There’s a New Molecular Target for IPF, Research Shows
Sourced from: James Heilman, MD / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

There’s a New Molecular Target for IPF, Research Shows

An estimated 13-20 out of every 100,000 people around the globe have idiopathic pulmonary fibrosis (IPF). The condition often has a poor prognosis (3-5 years following diagnosis) and there are…

Continue Reading There’s a New Molecular Target for IPF, Research Shows
Make Research Remote, Hear Rare Voices`
source: pixabay.com

Make Research Remote, Hear Rare Voices`

As the pandemic shifted cocktail hour onto zoom and professors posted their full course material online, many rare patients reveled. Not because we weren’t suffering through the pandemic too, but…

Continue Reading Make Research Remote, Hear Rare Voices`
Despite the Pandemic, 2020 Had More Drug Development for Rare Diseases than 2019
Sourced from publicdomainpictures.net (https://www.publicdomainpictures.net/en/view-image.php?image=275669&picture=chemical-research)

Despite the Pandemic, 2020 Had More Drug Development for Rare Diseases than 2019

Rare Disease Day is February 28th. This year, it caused a lot of reflection among healthcare professionals and families impacted by rare conditions. How has the pandemic shifted progress in…

Continue Reading Despite the Pandemic, 2020 Had More Drug Development for Rare Diseases than 2019
RT001 Granted Rare Pediatric Disease Designation for INAD, FA
source: pixabay.com

RT001 Granted Rare Pediatric Disease Designation for INAD, FA

In a press release from late February 2021, biopharmaceutical company Retrotope shared that its lead drug candidate, RT001, received Rare Pediatric Disease designation for the treatment of patients with Friedreich's…

Continue Reading RT001 Granted Rare Pediatric Disease Designation for INAD, FA
SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial
source: pixabay.com

SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial

Since its inception, life sciences company Solid Biosciences Inc. has been working to develop treatment options for patients with Duchenne muscular dystrophy (DMD). According to a recent press release, the…

Continue Reading SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial

Levodopa, Parkinson’s Disease, and Dyskinesia: The Benefits of Levodopa May Not Outweigh the Risk

The majority of Parkinson’s patients treated with Levodopa experience relief from the major motor effects of Parkinson’s. However, according to a recent article in Biospace, after prolonged use of Levodopa…

Continue Reading Levodopa, Parkinson’s Disease, and Dyskinesia: The Benefits of Levodopa May Not Outweigh the Risk

Oncology Researchers Are Beginning to Focus on Ways to Stop Uncontrolled Cancerous Cell Division

According to a recent article in Fierce Biotech, most cancers progress through constant cell division. Scientists at Vanderbilt University are determined to find the reason for this mysterious cell division.…

Continue Reading Oncology Researchers Are Beginning to Focus on Ways to Stop Uncontrolled Cancerous Cell Division